Natural Investments LLC Takes $336,000 Position in Boston Scientific Corporation (NYSE:BSX)

Key Points

• Natural Investments LLC has acquired a new position in Boston Scientific Corporation, purchasing 3,334 shares valued at approximately $336,000 during the first quarter.
• Boston Scientific stocks have received multiple analyst upgrades, with firms like Oppenheimer and Evercore ISI raising their target prices, reflecting a general trend towards a "strong-buy" rating.
• In recent insider transactions, CEO Michael F. Mahoney sold 164,443 shares of the company, indicating a significant decrease of 10.02% in his position, while Director Edward J. Ludwig also sold 4,000 shares in July.

Natural Investments LLC acquired a new stake in Boston Scientific Corporation (NYSE:BSX - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 3,334 shares of the medical equipment provider's stock, valued at approximately $336,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Colonial Trust Co SC boosted its position in Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 260 shares during the period. Investment Management Corp VA ADV bought a new position in Boston Scientific during the fourth quarter worth $25,000. Sunbeam Capital Management LLC bought a new position in Boston Scientific during the fourth quarter worth $26,000. Ameriflex Group Inc. bought a new position in Boston Scientific during the fourth quarter worth $31,000. Finally, Fourth Dimension Wealth LLC bought a new position in Boston Scientific during the fourth quarter worth $36,000. 89.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on BSX shares. Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Erste Group Bank raised Boston Scientific to a "strong-buy" rating in a report on Thursday, May 8th. Oppenheimer lifted their target price on Boston Scientific from $110.00 to $118.00 and gave the stock a "market perform" rating in a report on Thursday, July 24th. Royal Bank Of Canada reissued an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Finally, Evercore ISI lifted their target price on Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Two research analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, Boston Scientific presently has an average rating of "Buy" and an average price target of $117.50.

Insider Transactions at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the transaction, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael F. Mahoney sold 164,443 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the completion of the transaction, the chief executive officer owned 1,476,882 shares in the company, valued at $153,137,894.58. This trade represents a 10.02% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 345,029 shares of company stock worth $35,976,603. Company insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

Boston Scientific stock opened at $104.71 on Wednesday. The business has a 50 day moving average of $103.65 and a 200-day moving average of $102.00. Boston Scientific Corporation has a 1 year low of $73.02 and a 1 year high of $108.94. The company has a market capitalization of $155.15 billion, a P/E ratio of 62.33, a P/E/G ratio of 2.57 and a beta of 0.66. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.88.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.62 EPS. On average, equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.